<DOC>
	<DOCNO>NCT01215877</DOCNO>
	<brief_summary>The intravenously administer taxanes , docetaxel paclitaxel , alone combination chemotherapy agent active patient advance metastatic bladder cancer , agent class promising treatment option patient . Tesetaxel orally administer taxane development treatment subject advance cancer . This study conduct determine efficacy safety tesetaxel administer patient previously treat chemotherapy progressive metastatic transitional cell carcinoma urothelium .</brief_summary>
	<brief_title>Tesetaxel Previously Treated Patients With Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>At least 18 year age Histologically confirm diagnosis urothelial carcinoma bladder , urethra , ureter , renal pelvis Measurable disease ( revised RECIST ; Version 1.1 ) Karnofsky performance status â‰¥ 60 % Previously treat 1 doublet triplet regimen regimen contain gemcitabine platinum agent Adequate bone marrow , hepatic , renal function , specify protocol At least 4 week recovery effect prior surgery , prior radiotherapy , therapy approve investigational agent Ability swallow oral soliddosage form medication Known metastasis symptom metastasis central nervous system Significant medical disease cancer Presence neuropathy &gt; Grade 1 ( NCI CTC , Version 4.0 ) Prior treatment taxane tubulintargeted agent ( eg , indibulin ) vinca alkaloid Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway Pglycoprotein activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Previously treat patient</keyword>
	<keyword>Tesetaxel</keyword>
	<keyword>Oral taxane</keyword>
</DOC>